London Stock Exchange Gr Stock (OTC: LNSTY)

London Stock Exchange Gr (OTC:LNSTY) Stock, Quote.Headers.trade-ideas

London Stock Exchange Group is a fully integrated financial exchange company covering the financial market value chain from primary and secondary markets across multiple asset classes over data, index and analytics down to clearing and post-trading reporting. With the acquisition of Refinitiv, LSEG generates about two thirds of its revenue from data and analytics including its FTSE Russell and WM/Refinitiv benchmarks as well as data feeds and terminals. The group is also a majority shareholder in Tradeweb, one of the dominant global fixed income trading venues, as well as LCH, the largest clearing house for over-the-counter swaps globally.

News

Penny Stocks

Markets

AMZN

BABA

CPCAY

DTRUY

LNSTY

MSFT

Nestle Sponsored representing Registered Shares Series B

NSRGY

SFTBF

SFTBY

TSLA

Benzinga

BHP and Microsoft: An Unlikely Duo Boosting Copper Mining with AI

Amazon Delays Zero Emissions Goal, ChatGPT Makes Up Fake Legal Cases, New CFO for Unilever and Nestle: Today&#39;s Top Stories

Equities

Large Cap

Management

JMPLY

Nestle Picks LSEG Executive As Its New CFO

Long Ideas

Short Ideas

Technicals

Trading Ideas

Microsoft Corporation (NASDAQ: MSFT) spiked up almost 3% at one point on Monday before running into a group of sellers who knocked the stock down about 1% from the high-of-day.

Microsoft Charges Higher On London Stock Exchange Group Deal: Will This New Trend Form?

LONDON STOCK EX UNSP/ADR by London Stock Exchange Ltd.

London Stock Exchange Group PLC

BKYI

BIO-key Announces Expansion Of Identity Management Solutions For British Columbia, Adding 10,000 Users To Existing WEB-key Deployment Integrated With Broadcom's SiteMinder

EF Hutton analyst Jason Kolbert initiates coverage on Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) with a Buy rating and announces Price Target of $29.

Price Target

Initiation

Analyst Ratings

IMNN

EF Hutton Initiates Coverage On Imunon with Buy Rating, Announces Price Target of $29

Biotech

General

VTGN

Vistagen Initiates PALISADE-4 Phase 3 Study Of Fasedienol For Acute Treatment Of Social Anxiety Disorder

Contracts

AMPX

Amprius Receives Two Contracts To Supply 40 ah High-Performance Cells For Light Electric Vehicle Applications; Contracts' Total Exceeds $20M

Kazia Therapeutics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington.
Dr. John Friend, CEO Kazia Therapeutics presented preliminary data from a Phase 1 first-in-human clinical trial evaluating the safety and tolerability of EVT801, a highly selective small molecule VEGFR3 inhibitor targeting tumour angiogenesis. The Phase 1 study met its primary objectives, with the maximal tolerated dose identified at 500mg twice a day (BID). The Phase 1 study also identified the recommended Phase 2 dose starting at 400mg BID. It was observed that EVT801 was tolerated across all doses, with the majority of toxicities being mild to moderate and transient in nature.
Key points of the presentation included:
<ul>
<li>A total of 26 patients were treated across 6 dosing cohorts ranging from 50mg once daily (QD) to 500mg twice daily (BID)</li>
<li>Patients with eleven different cancer types (ex. colon, renal cell, pancreatic) were enrolled in the study, with heavily pretreated advanced ovarian cancer being the most prevalent indication (11 patients)</li>
<li>Biomarkers have shown strong VEGFR3 expression in multiple indications, including ovarian cancer</li>
<li>Encouraging clinical activity in High Grade Serous ovarian cancer patients with forty-six percent (46%) having stable disease or for at least three cycles, including two patients who received 9 cycles</li>
<li>One patient had a partial response (-39% decrease) after 2 cycles of EVT801 therapy</li>
</ul>

KZIA

Kazia Therapeutics Announces Presentation Of EVT801 Clinical Data At 15th Biennial Ovarian Cancer Research Symposium

Piper Sandler analyst Yasmeen Rahimi reiterates NewAmsterdam Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) with a Overweight and maintains $37 price target.

Reiteration

NAMS

Piper Sandler Reiterates Overweight on NewAmsterdam Pharma, Maintains $37 Price Target

DA Davidson analyst Gil Luria downgrades Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) from Buy to Neutral and announces $475 price target.

Downgrades

DA Davidson Downgrades Microsoft to Neutral, Announces $475 Price Target

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk on Saturday said that buses will not be needed when the EV giant ultimately achieves autonomous driving capability with its full self-driving (FSD) driver assistance software. 
What Happened: If electric buses need to be equipped with diesel generators for heat when the temperature drops, it means that their battery packs are too small, Musk said on social media platform X. The CEO was responding to a user by the name of Peter Imanuelsen who alleged that several buses in Norway had to be equipped with diesel generators to warm the cabin during the last winter.
&#8220;&#8230;busses will not be needed when Tesla rolls out unsupervised full self-driving, as they will take people point to point for a similar cost to a bus ticket,&#8221; the CEO added, implying that the cost of availing Tesla robotaxis would be low once they enter operations. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Then the battery packs of the busses are too small. Teslas can operate well even above the Arctic Circle. Also, busses will not be needed when Tesla rolls out unsupervised full self-driving, as they will take people point to point for a similar cost to a bus ticket.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1837506412357824960?ref_src=twsrc%5Etfw">September 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Musk is now aiming to make Tesla vehicles capable of autonomous driving with new iterations of its FSD. The software currently requires active driver supervision but will enable autonomous driving in the future, according to the CEO. The company is also looking to unveil its <a href="https://www.benzinga.com/news/24/07/39929718/tesla-robotaxi-unveiling-set-for-oct-10-here-are-the-updates-from-company-ceo-elon-musk-on-its-upcom">dedicated robotaxi offering in October.</a> 
Musk expects his company's robotaxi fleet to function like a&nbsp;<a href="https://www.benzinga.com/news/24/04/38396288/teslas-robotaxi-to-be-called-cybercab-elon-musk-says-self-driving-fleet-will-be-like-combination-of" target="_blank" rel="noreferrer noopener">combination of Airbnb and Uber</a>. While a certain portion of the fleet will be owned by Tesla, individual Tesla customers can also add or subtract their vehicles to the robotaxi fleet at will for additional income. As for riders, they can summon a car using the Tesla App, Musk said.
Earlier this month, Tesla said in a post on X that it will focus on improving FSD throughout this year in the U.S. and deploying the software on its latest vehicle offering – the Cybertruck- before rolling it out in Europe and China in the first quarter of 2025.
During Tesla&#8217;s second-quarter earnings call in July, Musk said that unsupervised driving on a Tesla could be possible <a href="https://www.benzinga.com/news/24/09/40808924/tesla-robotaxi-event-to-be-held-in-los-angeles-on-1010-says-senior-company-exec-existing-shareholder">by late 2024 or in 2025.</a> However, the CEO is known for overestimating the capabilities of his company&#8217;s different offerings and for providing changing timelines. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40968441/russian-presidents-ally-ramzan-kadyrov-says-elon-musk-remotely-turned-off-his-cybertruck-in-russia">Russian President&#8217;s Ally Ramzan Kadyrov Says Elon Musk Remotely Turned Off His Cybertruck In Russia</a></li>
</ul>
Image via Shutterstock

Tech

Elon Musk Says Buses Won't Be Needed Once Tesla Robotaxis Start Operating: 'Will Take People Point To Point For A Similar Cost'

Macro Economic Events

Econ #s

Economics

USA Chicago Fed National Activity For August 0.12 Vs -0.20 Est.; -0.42 Prior (Revised From -0.34)

Telos Expands Enrollment And Renewal Options By Opening New Locations

Canaccord Genuity analyst Joseph Vafi initiates coverage on Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy rating and announces Price Target of $16.

Core Scientific, Inc. - Class A Common Stock

CORZ

Canaccord Genuity Initiates Coverage On Core Scientific with Buy Rating, Announces Price Target of $16

Piper Sandler analyst Korinne Wolfmeyer maintains Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Neutral and raises the price target from $20 to $21.

KVUE

Piper Sandler Maintains Neutral on Kenvue, Raises Price Target to $21

TOVX

Theriva Biologics Reaches Target Patient Enrollment In VIRAGE Phase 2b Trial Of VCN-01 With Gemcitabine/Nab-Paclitaxel For Metastatic Pancreatic Cancer Treatment, Conducted Across 15 Sites In Spain And USA

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/09/20/final-trades-samsara-constellation-energy-aptiv-and-the-indy.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management said Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) <a href="https://www.benzinga.com/quote/IOT/earnings">hit an all-time high on Friday.</a>
On Sept. 5, Samsara reported quarterly earnings of 5 cents per share which beat the analyst consensus estimate of 1 cent per share. The company reported quarterly sales of $300.20 million which beat the analyst consensus estimate of $289.54 million.
Stephen Weiss of Short Hills Capital Partners picked iShares India 50 ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDY#NASDAQ">INDY</a>), saying declining interest rates are good for emerging market economies.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage her</a><a href="https://www.benzinga.com/premarket/">e</a>
Jenny Van Leeuwen Harrington of Gilman Hill Asset Management said Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) trades at 9.5 times earnings, with 20% earnings growth over the next three years.
On Sept. 20, Wells Fargo analyst Colin Langan upgraded the rating for Aptiv from Equal-Weight to Overweight and raised the price target from $78 to $87.
Joseph M. Terranova of Virtus Investment Partners named Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) as his final trade.
On Sept. 20, Constellation Energy announced it signed a 20-year power purchase agreement with Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>). The deal entails the launch of the Crane Clean Energy Center (CCEC) and the restart of Three Mile Island Unit 1, which was <a href="https://www.benzinga.com/markets/equities/24/09/40957437/microsoft-taps-constellation-for-20-year-carbon-free-power-3-400-jobs-coming-to-pennsylvania">closed five years ago.</a>
Price Action:
<ul>
<li>Samsara gained 3.8% to close at $49.39 during Friday's session.</li>
<li>Aptiv shares fell 1% to settle at $69.84 on Friday.</li>
<li>iShares India 50 ETF gained 1.2% during Friday's session.</li>
<li>Constellation Energy shares jumped 22.3% to close at $254.98 on Friday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>
Image courtesy of Samsara

Media

APTV

INDY

Samsara, Aptiv, Constellation Energy And More On CNBC's 'Final Trades'

Matthews International Corporation (NASDAQ GSM: MATW) (the "Company") today announced a proposed private offering of senior secured second lien notes due 2027 (the "Notes"). At or prior to the closing of the offering of the Notes, the Company intends to amend its senior credit facility to, among other things, permit the Notes to be secured by a second priority lien on substantially all of our and certain of our domestic subsidiaries' assets, and the Company and certain of its domestic subsidiaries intend to enter into a second amended and restated pledge and security agreement pursuant to which the Company and such subsidiaries will grant to the secured parties under the senior credit facility a first priority lien on substantially all of the Company's and such subsidiaries' assets.
The Company intends to use the net proceeds of the offering, together with borrowings under the Company's senior credit facility, to redeem all of its outstanding 5.25% senior notes due December 1, 2025 (the "Existing 2025 Notes") on or about October 25, 2024, and to pay accrued and unpaid interest on the Existing 2025 Notes to, but not including, the date of redemption, and to satisfy and discharge the indenture governing the Existing 2025 Notes.

Offerings

MATW

Matthews International Announced A Proposed Private Offering Of Senior Secured Second Lien Notes Due 2027

Jabil Expands Silicon Photonics Capabilities At Ottawa Site To Support New Product Introductions For Hyperscalers And AI Data Centers, Set To Roll Out In Q4 2024

Morgan Stanley analyst David Arcaro maintains Public Service Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>) with a Overweight and raises the price target from $83 to $95.

Morgan Stanley Maintains Overweight on Public Service Enterprise, Raises Price Target to $95

Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (Nasdaq:&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260606-1&amp;h=4181839075&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Finnovative-eyewear-inc-announces-exercise-of-warrants-302236683.html%23financial-modal&amp;a=LUCY">LUCY</a>), the developer of smart eyewear under the Lucyd&#xAE;, Nautica&#xAE;, Eddie Bauer&#xAE; and Reebok&#xAE; brands, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 263,160&nbsp;shares of the Company's common stock originally issued by the Company on&nbsp;May 29, 2024, each having an original exercise price of&nbsp;$9.50&nbsp;per share, at an exercise price of&nbsp;$9.875&nbsp;per share. The closing of the warrant exercise transaction is expected to occur on or about&nbsp;September 24, 2024, subject to satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-279873).
The gross proceeds to the Company from the exercise of the warrants are expected to be approximately&nbsp;$2.6 million, prior to deducting placement agent fees and offering expenses. The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes.

LUCY

Innovative Eyewear Announces Exercise Of Warrants For $2.6M Gross Proceeds For The Immediate Exercise Of Certain Outstanding Warrants To Purchase An Aggregate Of 263,160 Shares Of Common Stock Originally Issued By The Company On May 29, 2024, Each Having An Original Exercise Price Of $9.50 Per Share, At An Exercise Price Of $9.875 Per Share

Cantor Fitzgerald analyst Prakhar Agrawal reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Overweight.

MLTX

Cantor Fitzgerald Reiterates Overweight on MoonLake

Alaska Airlines Expands Cargo Division Following Hawaiian Airlines Merger, Names Ian Morgan VP Of Cargo And Jason Berry Executive VP Of Cargo For Alaska Air Group

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

London Stock Exchange Gr

London Stock Exchange Gr (LNSTY) Forecast

London Stock Exchange Gr (OTC:LNSTY) Stock, Quote.Headers.trade-ideas